Volastra Therapeutics Email Format
Biotechnology ResearchNew York, United States11-50 Employees
Volastra Therapeutics is a biotechnology research company based in New York that conducts drug discovery and therapeutics development for cancer. The company focuses on exploiting chromosomal instability (CIN) as a therapeutic vulnerability and advancing a synthetic lethal and immune-activating pipeline. It was founded by Lewis Cantley, Olivier Elemento, and Samuel Bakhoum. Volastra has two KIF18A inhibitors in Phase 1 clinical trials targeting cancers with high CIN. The organization has 11–50 employees and is located at 1361 Amsterdam Avenue 520, New York, NY 10027; more information is available on its website at volastratx.com.